Skip to content

Study · Case report or series · n = 1 · 2023

1 result

Eosinophil-related diseases during treatment with glucagon-like peptide one receptor (GLP-1 RA): a case report and review of the literature.

Posso-Osorio I, Vargas-Potes CJ, Mejía M, Cañas CA

Clinical rheumatology18 May 2023Cited by 11 (Europe PMC)

PMID37199890 (opens in a new tab)PMCIDPMC10412476 (opens in a new tab)DOI10.1007/s10067-023-06612-w (opens in a new tab)PepBankPUB-37199890
Download PDFPubMedAsk about this study
Jump to 1 result

Summary

Glucagon-like peptide one-receptor agonists (GLP-1 RA) are drugs that differ in their pharmacological composition and homology to human GLP-1 and are used most frequently for the treatment of type 2 diabetes and weight loss. There are isolated reports of eosinophilic adverse reactions associated with GLP-1 RA. We present the case of a 42-year-old female patient who, after starting weekly subcutaneous semaglutide, developed eosinophilic fasciitis with favorable clinical evolution after the discontinuation of semaglutide and the initiation of immunosuppression. A review of the eosinophilic adverse events that have been previously reported with GLP-1 RA is provided.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study1

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanCase report or seriesSafety outcome

    In a 42-year-old woman, eosinophilic fasciitis developed after starting weekly subcutaneous semaglutide and improved after semaglutide was stopped and immunosuppression began.

    In plain wordsIn one woman, an inflammatory condition called eosinophilic fasciitis developed after weekly semaglutide and improved after the drug was stopped and immune-suppressing treatment began.

    Peptide
    Semaglutide
    Outcome
    IncreaseEosinophilic fasciitis during semaglutide treatment
    Study

    n = 1

    Outcome group
    Adverse events · Immune and inflammation
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    developed eosinophilic fasciitis with favorable clinical evolution after the discontinuation of semaglutide and the initiation of immunosuppression.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:50 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.